Cargando…

A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor

INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular en...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyajima, Keiichiro, Urabe, Fumihiko, Shunsuke, Tsuzuki, Shun, Sato, Takahashi, Hiroyuki, Asano, Koji, Yanagaki, Mitsuru, Matsumoto, Michinori, Ikegami, Toru, Kimura, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622189/
https://www.ncbi.nlm.nih.gov/pubmed/37928285
http://dx.doi.org/10.1002/iju5.12625
_version_ 1785130486452977664
author Miyajima, Keiichiro
Urabe, Fumihiko
Shunsuke, Tsuzuki
Shun, Sato
Takahashi, Hiroyuki
Asano, Koji
Yanagaki, Mitsuru
Matsumoto, Michinori
Ikegami, Toru
Kimura, Takahiro
author_facet Miyajima, Keiichiro
Urabe, Fumihiko
Shunsuke, Tsuzuki
Shun, Sato
Takahashi, Hiroyuki
Asano, Koji
Yanagaki, Mitsuru
Matsumoto, Michinori
Ikegami, Toru
Kimura, Takahiro
author_sort Miyajima, Keiichiro
collection PubMed
description INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular endothelial growth factor for metastatic HCC. A contrast‐enhanced CT revealed a 15 × 15 mm soft tissue mass protruding from the posterior bladder wall. Cystoscopy further revealed a solitary submucosal mass located on the posterior wall. The patient underwent transurethral resection of bladder tumor. The pathological findings were consistent with a diagnosis of bladder metastasis from HCC. Following a 3‐week interval after the surgical intervention, salvage therapy was resumed. CONCLUSION: During follow‐up after TUR‐BT in HCC patients who present with a bladder tumor, the possibility of HCC metastases to the urinary bladder should be excluded.
format Online
Article
Text
id pubmed-10622189
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-106221892023-11-03 A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor Miyajima, Keiichiro Urabe, Fumihiko Shunsuke, Tsuzuki Shun, Sato Takahashi, Hiroyuki Asano, Koji Yanagaki, Mitsuru Matsumoto, Michinori Ikegami, Toru Kimura, Takahiro IJU Case Rep Case Reports INTRODUCTION: Here we present a rare case of hepatocellular carcinoma metastasis to the urinary bladder in a patient with metastatic HCC. CASE PRESENTATION: An 83‐year‐old man developed gross hematuria during combined treatment with an anti‐programmed death‐ligand 1 inhibitor and an anti‐vascular endothelial growth factor for metastatic HCC. A contrast‐enhanced CT revealed a 15 × 15 mm soft tissue mass protruding from the posterior bladder wall. Cystoscopy further revealed a solitary submucosal mass located on the posterior wall. The patient underwent transurethral resection of bladder tumor. The pathological findings were consistent with a diagnosis of bladder metastasis from HCC. Following a 3‐week interval after the surgical intervention, salvage therapy was resumed. CONCLUSION: During follow‐up after TUR‐BT in HCC patients who present with a bladder tumor, the possibility of HCC metastases to the urinary bladder should be excluded. John Wiley and Sons Inc. 2023-08-13 /pmc/articles/PMC10622189/ /pubmed/37928285 http://dx.doi.org/10.1002/iju5.12625 Text en © 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Miyajima, Keiichiro
Urabe, Fumihiko
Shunsuke, Tsuzuki
Shun, Sato
Takahashi, Hiroyuki
Asano, Koji
Yanagaki, Mitsuru
Matsumoto, Michinori
Ikegami, Toru
Kimura, Takahiro
A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title_full A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title_fullStr A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title_full_unstemmed A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title_short A case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
title_sort case of urinary bladder metastasis of hepatocellular carcinoma following use of immunotherapy/tyrosine kinase inhibitor
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622189/
https://www.ncbi.nlm.nih.gov/pubmed/37928285
http://dx.doi.org/10.1002/iju5.12625
work_keys_str_mv AT miyajimakeiichiro acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT urabefumihiko acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT shunsuketsuzuki acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT shunsato acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT takahashihiroyuki acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT asanokoji acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT yanagakimitsuru acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT matsumotomichinori acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT ikegamitoru acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT kimuratakahiro acaseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT miyajimakeiichiro caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT urabefumihiko caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT shunsuketsuzuki caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT shunsato caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT takahashihiroyuki caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT asanokoji caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT yanagakimitsuru caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT matsumotomichinori caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT ikegamitoru caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor
AT kimuratakahiro caseofurinarybladdermetastasisofhepatocellularcarcinomafollowinguseofimmunotherapytyrosinekinaseinhibitor